-
Find a Clinical Trial
-
Get Connected
-
Latest Report
-
Get Involved
-
About MRA
The problem with the existing AI algorithms is that they have been developed using images of moles from light skinned (white) individuals. As a result, they often are not sensitive enough in people with darker skin. Dr. Albert Chiou, young investigator on the L’Oréal Dermatological Beauty Brands-MRA Team Science Award, and his colleagues are working to improve AI, so it can help all people, regardless of skin tone.
While all patients with advanced melanoma can be treated with checkpoint immunotherapies, patients with tumors containing the BRAF mutation can also be treated with targeted therapies. However, until now, doctors have had little prospective data to determine which treatment approach should be started first. A new study led by Dr. Michael Atkins provides practice-changing insight.
You may have heard of Opdualag, a new therapy that recently earned FDA approval for advanced melanoma. Opdualag, which combines two different immunotherapies into one medicine, is earning attention as an effective – and more easily tolerated – combination therapy.
This Mom of three enrolled in a neoadjuvant clinical trial for Stage 3 melanoma. After two infusions of Opdualag, Shannon underwent a successful surgery where doctors removed all affected lymph nodes and tested them, revealing No Evidence of Disease (NED).